Cantabio Pharmaceuticals Inc. (CTBO) Targets Alzheimer’s

More than 700,000 seniors are expected to die this year from Alzheimer’s disease. It is the 6th leading cause of death in the U.S. The need for treatments is dire and Cantabio is aiming to develop a novel therapy to treat the disease.

The company recently announced a new preclinical therapeutic program for Alzheimer’s Disease which it is pursuing through its drug discovery partnership with NovAliX. This program is aimed at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a key element in the onset and progression of Alzheimer’s disease.

The program is the result of collaborative work between Cantabio and NovAliX and is based on the discovery of novel small molecules that interact with the Abeta peptide, which were identified using NovAliX’s high throughput chemical microarray based surface plasmon resonance (SPR-WORM) screen, a unique high throughput biophysics based binding assay platform.

Dr. Gergely Toth, Cantabio’s CEO, has said, “We are delighted to announce this exciting program, which fits in well with Cantabio’s existing portfolio of candidates and further demonstrates our innovative pharmacological chaperone based drug discovery approach in the field of Alzheimer’s, Parkinson’s and related diseases. Our collaboration with NovAliX has been highly productive and has helped us to develop novel therapeutic candidates using their unique high throughput SPR-WORM screen. NovAliX has always been very supportive of our approach and vision; we look forward to continuing to work with them as our industrial partner in drug discovery and to continue to develop candidate therapies in this exciting and highly promising area. ”

NovAliX’s CEO Dr Denis Zeyer said, “We are happy to be working with the Cantabio team to develop exciting new technologies and to showcase the very high potential of the SPR-WORM screen to identify valuable chemical starting points for the targeting of protein – protein interactions. Cantabio’s approach to drug discovery has, we believe, high potential to produce novel, first in class therapies in these disease areas, which have a very high unmet need for disease treating drugs.”

Disclaimer: We have no position in Cantabio Pharmaceuticals Inc. (CTBO) and have not been compensated for this article.